| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pe...
-SEC Filing
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology c...
Roth Capital analyst Boobalan Pachaiyappan maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target from $1...